AsHenriTermeer, chiefexecutiveof Genzyme, a bigbiotechnologyfirm, argues, “the blockbuster modelbecomeslessimportant over time as specialised therapies take off.”
"Thymoglobulin is an excellent product that has the potential to transform the way transplant teams manage the care of their patients, " said Genzyme Chief Executive HenriTermeer in a prepared statement.